Kosaka H, Sugimoto R, Kinoshita M, Yasuda S, et al. Impact of TOPAZ-1 eligibility on the survival benefit of durvalumab plus gemcitabine-cisplatin in advanced biliary tract cancer: a multicenter real-world study. J Gastroenterol 2026 Apr 12. doi: 10.1007/s00535-026-02412.
PMID: 41966637